A Dose and Schedule Finding Trial With AMG 531 for CIT in Adults With Lymphoma

2014-08-27 03:46:29 | BioPortfolio


The purpose of this study is to identify a well-tolerated, effective dose and schedule of AMG 531 for the treatment of CIT in subjects with lymphoma receiving multi-cycle chemotherapy.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Chemotherapy-Induced Thrombocytopenia


AMG 531





Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:46:29-0400

Clinical Trials [526 Associated Clinical Trials listed on BioPortfolio]

Heparin Induced Thrombocytopenia: Pharmacoeconomics

Patients at BWH receiving unfractionated heparin or enoxaparin who subsequently develop heparin induced thrombocytopenia will be identified via a computer generated report designed for the...

Heparin-Induced Thrombocytopenia Registry

The purpose of the Heparin Induced Thrombocytopenia Registry is to explore the frequency of heparin-induced thrombocytopenia (HIT) at Brigham and Women's Hospital and to assess its mortali...

Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)

This research study is studying a drug as a possible treatment for heparin induced thrombocytopenia (HIT) or Heparin-induced Thrombocytopenia and Thrombosis (HITT). The drug involved in t...

Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients

Chemotherapy Induced Thrombocytopenia is a common side-effect of bone marrow suppression as a result of a chemotherapy treatment. AS101 is a tellurium based small compound with immunomodul...

Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

The purpose of this study is to determine how safe and effective fondaparinux is in treating patients with suspected or confirmed heparin-induced thrombocytopenia (HIT).

PubMed Articles [11108 Associated PubMed Articles listed on BioPortfolio]

Linezolid-induced thrombocytopenia increases mortality risk in intensive care unit patients, a 10 year retrospective study.

Linezolid-induced thrombocytopenia is one of the many confounding conditions in critically ill patients. It is rare but prognostic importance of linezolid-induced thrombocytopenia in ICU population ha...

Rapid onset severe thrombocytopenia following reexposure to piperacillin-tazobactam: report of two cases and review of the literature.

Pipercillin-tazobactam is a frequently used antibiotic that has a broad spectrum of antibacterial activity. The development of severe thrombocytopenia following the use of piperacillin-tazobactam is u...

Heparin-induced thrombocytopenia in a cardiac surgery patient with early and persistent thrombocytopenia and initial negative immunological and functional assays.

Characterization of hospitalized cardiovascular patients with suspected heparin-induced thrombocytopenia.

Little is known about heparin-induced thrombocytopenia (HIT), a pro-thrombotic, potentially life-threatening immune-mediated reaction to heparin exposure, in conservative and interventional cardiovasc...

Avatrombopag: First Global Approval.

Avatrombopag (Doptelet) is an orally bioavailable, small molecule thrombopoietin receptor agonist that has been developed by Dova Pharmaceuticals for the treatment of thrombocytopenic disorders. In Ma...

Medical and Biotech [MESH] Definitions

FEVER accompanied by a significant reduction in NEUTROPHIL count associated with CHEMOTHERAPY.

Drug treatment designed to further diminish the disease toward complete remission following INDUCTION CHEMOTHERAPY. It helps to consolidate the gains during induction chemotherapy and may be followed by MAINTENANCE CHEMOTHERAPY.

Treatment designed to help prevent a relapse of a disease following the successful primary treatments (INDUCTION CHEMOTHERAPY and CONSOLIDATION CHEMOTHERAPY) with a long-term low-dose drug therapy.

Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.

A syndrome characterized by inflammation in the ILEUM, the CECUM, and the ASCENDING COLON. It is observed in cancer patients with CHEMOTHERAPY-induced NEUTROPENIA or in other immunocompromised individuals (IMMUNOCOMPROMISED HOST).

More From BioPortfolio on "A Dose and Schedule Finding Trial With AMG 531 for CIT in Adults With Lymphoma"

Quick Search


Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Searches Linking to this Trial